Author: gammy

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at CTAD 2025

TOKYO and CAMBRIDGE, Mass., Dec 4, 2025 – (JCN Newswire via SeaPRwire.com) –  Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the

More

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI(R)” for the Treatment of Early Alzheimer’s Disease in Japan

TOKYO and CAMBRIDGE, Mass., Nov. 28, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai

More